- Home
- BOLT vs LGVN Comparison
BOLT vs LGVN Comparison
Compare BOLT & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- LGVN
- Stock Information
- Founded
- BOLT 2015
- LGVN 2014
- Country
- BOLT United States
- LGVN United States
- Employees
- BOLT N/A
- LGVN N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BOLT Health Care
- LGVN Health Care
- Exchange
- BOLT Nasdaq
- LGVN Nasdaq
- Market Cap
- BOLT 22.6M
- LGVN 25.2M
- IPO Year
- BOLT 2021
- LGVN 2021
- Fundamental
- Price
- BOLT $0.49
- LGVN $1.52
- Analyst Decision
- BOLT Hold
- LGVN Strong Buy
- Analyst Count
- BOLT 5
- LGVN 3
- Target Price
- BOLT $1.25
- LGVN $8.67
- AVG Volume (30 Days)
- BOLT 136.2K
- LGVN 251.2K
- Earning Date
- BOLT 03-20-2025
- LGVN 02-25-2025
- Dividend Yield
- BOLT N/A
- LGVN N/A
- EPS Growth
- BOLT N/A
- LGVN N/A
- EPS
- BOLT N/A
- LGVN N/A
- Revenue
- BOLT $9,779,000.00
- LGVN $1,852,000.00
- Revenue This Year
- BOLT $9.87
- LGVN $208.32
- Revenue Next Year
- BOLT N/A
- LGVN $43.96
- P/E Ratio
- BOLT N/A
- LGVN N/A
- Revenue Growth
- BOLT 35.86
- LGVN 141.46
- 52 Week Low
- BOLT $0.46
- LGVN $0.77
- 52 Week High
- BOLT $1.56
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- BOLT 44.93
- LGVN 33.10
- Support Level
- BOLT $0.49
- LGVN $1.52
- Resistance Level
- BOLT $0.52
- LGVN $1.65
- Average True Range (ATR)
- BOLT 0.03
- LGVN 0.11
- MACD
- BOLT -0.00
- LGVN -0.02
- Stochastic Oscillator
- BOLT 24.24
- LGVN 17.65
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.